Wall Street Analyst Resumed VYNE Therapeutics Inc. [VYNE]. What else is Wall St. saying

Related

VYNE Therapeutics Inc. [NASDAQ: VYNE] price plunged by -21.45 percent to reach at -$0.21. The company report on January 13, 2022 that VYNE Therapeutics Divests Topical Minocycline Assets.

Transaction includes cash payments of $25 million and potential milestones of up to $450 million.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s immuno-inflammatory pipeline.

A sum of 16121776 shares traded at recent session while its average daily volume was at 2.47M shares. VYNE Therapeutics Inc. shares reached a high of $1.09 and dropped to a low of $0.77 until finishing in the latest session at $0.79.

The one-year VYNE stock forecast points to a potential upside of 86.38. The average equity rating for VYNE stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on VYNE Therapeutics Inc. [VYNE]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VYNE shares is $5.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VYNE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for VYNE Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 06, 2021.

The Average True Range (ATR) for VYNE Therapeutics Inc. is set at 0.13, with the Price to Sales ratio for VYNE stock in the period of the last 12 months amounting to 2.52. The Price to Book ratio for the last quarter was 0.70.

VYNE Stock Performance Analysis:

VYNE Therapeutics Inc. [VYNE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.99. With this latest performance, VYNE shares dropped by -32.86% in over the last four-week period, additionally sinking by -70.80% over the last 6 months – not to mention a drop of -88.10% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VYNE stock in for the last two-week period is set at 32.78, with the RSI for the last a single of trading hit 26.40, and the three-weeks RSI is set at 36.41 for VYNE Therapeutics Inc. [VYNE]. The present Moving Average for the last 50 days of trading for this stock 1.1336, while it was recorded at 0.9720 for the last single week of trading, and 2.5023 for the last 200 days.

Insight into VYNE Therapeutics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and VYNE Therapeutics Inc. [VYNE] shares currently have an operating margin of -448.13 and a Gross Margin at +93.37. VYNE Therapeutics Inc.’s Net Margin is presently recorded at -1217.40.

Return on Total Capital for VYNE is now -132.98, given the latest momentum, and Return on Invested Capital for the company is -365.02. Return on Equity for this stock declined to -482.20, with Return on Assets sitting at -295.61. When it comes to the capital structure of this company, VYNE Therapeutics Inc. [VYNE] has a Total Debt to Total Equity ratio set at 92.77. Additionally, VYNE Total Debt to Total Capital is recorded at 48.13, with Total Debt to Total Assets ending up at 37.11. Long-Term Debt to Equity for the company is recorded at 90.76, with the Long-Term Debt to Total Capital now at 47.08.

Reflecting on the efficiency of the workforce at the company, VYNE Therapeutics Inc. [VYNE] managed to generate an average of -$2,411,019 per employee. Receivables Turnover for the company is 2.65 with a Total Asset Turnover recorded at a value of 0.24.VYNE Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.60.

>> 7 Top Picks for the Post-Pandemic Economy <<

VYNE Therapeutics Inc. [VYNE] Insider Position Details

There are presently around $11 million, or 29.80% of VYNE stock, in the hands of institutional investors. The top three institutional holders of VYNE stocks are: VANGUARD GROUP INC with ownership of 2,436,432, which is approximately 0% of the company’s market cap and around 2.30% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 2,330,471 shares of the stock with an approximate value of $1.83 million in VYNE stocks shares; and FRANKLIN RESOURCES INC, currently with $1.51 million in VYNE stock with ownership of nearly 1.072% of the company’s market capitalization.

Positions in VYNE Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 26 institutional holders increased their position in VYNE Therapeutics Inc. [NASDAQ:VYNE] by around 1,336,993 shares. Additionally, 37 investors decreased positions by around 5,095,371 shares, while 18 investors held positions by with 8,055,422 shares. The mentioned changes placed institutional holdings at 14,487,786 shares, according to the latest SEC report filing. VYNE stock had 8 new institutional investments in for a total of 218,178 shares, while 16 institutional investors sold positions of 705,905 shares during the same period.